Yoshio Terada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoshio Terada has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Fumiaki Marumo
The Second Department of Internal Medicine, Tokyo Medical and Dental University
5 shared publicationsSei Sasaki
4 shared publicationsMichio Kuwahara
Tokyo Medical and Dental University
3 shared publicationsOsamu Nakashima
Tokyo Medical and Dental University
3 shared publicationsSeiji Inoshita
Tokyo Medical and Dental University
3 shared publications- Takashi Akiba
Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
2 shared publications
Latest Publications
- 1 April 2009
- Vol. 50 (4) , 295-9
[Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction].
The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan. We examined the serum concentration of thalidomide 12 and 16 hours after administration in 5 patients with MM (one with normal renal function and four with renal insufficiency, including one on hemodialysis (HD)) taking 100-200 mg/day. Concentrations 12 and 16 hours after administration corresponded to those before and after HD, respectively, in the patient on HD. The thalidomide concentration was not significantly increased by renal insufficiency. We could not detect any correlation between the concentration of thalidomide and its clinical effect. Since the elimination of thalidomide during HD seems to be greater than during the same period on a non-HD day, it was suggested that thalidomide could be eliminated by HD. The concentrations 12 hours after administration were similar with or without HD. From these results, even in Japanese patients, the thalidomide dosage need not be modified for renal insufficiency and HD.
- 1 April 2009
- Vol. 50 (4) , 295-9
[Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction].
The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan. We examined the serum concentration of thalidomide 12 and 16 hours after administration in 5 patients with MM (one with normal renal function and four with renal insufficiency, including one on hemodialysis (HD)) taking 100-200 mg/day. Concentrations 12 and 16 hours after administration corresponded to those before and after HD, respectively, in the patient on HD. The thalidomide concentration was not significantly increased by renal insufficiency. We could not detect any correlation between the concentration of thalidomide and its clinical effect. Since the elimination of thalidomide during HD seems to be greater than during the same period on a non-HD day, it was suggested that thalidomide could be eliminated by HD. The concentrations 12 hours after administration were similar with or without HD. From these results, even in Japanese patients, the thalidomide dosage need not be modified for renal insufficiency and HD.
- 1 January 2001
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 34 (1) , 33-39
Estrogen receptor gene polymorphism is associated with bone mineral density in hemodialyzed patients.
- 1 January 2001
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 34 (1) , 33-39
Estrogen receptor gene polymorphism is associated with bone mineral density in hemodialyzed patients.
- Open Access
- 1 January 2001
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 40 (5) , 424-427
Glomerulonephritis after Methicillin-resistant Staphylococcus aureus Infection Resulting in End-stage Renal Failure.
A 58-year-old man developed proteinuria and renal dysfunction following pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin was administered, and prednisolone pulse therapy and plasmapheresis were performed. Subsequently, serum creatinine was decreased. Eight months later, creatinine and CRP were again elevated, and MRSA was detected. Vancomycin was again administered and plasmapheresis was performed. However, renal function was not improved and continuous hemodialysis was initiated. This case indicates that complete eradication of MRSA is necessary to treat MRSA-associated glomerulonephritis, and if this is not attained, a permanent loss of renal function occurs.
- 1 January 2001
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 40 (5) , 424-427
Open AccessGlomerulonephritis after Methicillin-resistant Staphylococcus aureus Infection Resulting in End-stage Renal Failure.
A 58-year-old man developed proteinuria and renal dysfunction following pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin was administered, and prednisolone pulse therapy and plasmapheresis were performed. Subsequently, serum creatinine was decreased. Eight months later, creatinine and CRP were again elevated, and MRSA was detected. Vancomycin was again administered and plasmapheresis was performed. However, renal function was not improved and continuous hemodialysis was initiated. This case indicates that complete eradication of MRSA is necessary to treat MRSA-associated glomerulonephritis, and if this is not attained, a permanent loss of renal function occurs.
- 1 October 1999
- Published by Elsevier in Kidney International
- Vol. 56 (4) , 1378-1390
TGF-βbgr-activating kinase-1 inhibits cell cycle and expression of cyclin D1 and A in LLC-PK1 cells
- 1 October 1999
- Published by Elsevier in Kidney International
- Vol. 56 (4) , 1378-1390
TGF-βbgr-activating kinase-1 inhibits cell cycle and expression of cyclin D1 and A in LLC-PK1 cells
- 1 October 1999
- Published by Elsevier in Kidney International
- Vol. 56 (4) , 1258-1261
Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade
- 1 October 1999
- Published by Elsevier in Kidney International
- Vol. 56 (4) , 1258-1261
Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade
- 1 August 1999
- Published by Elsevier in Kidney International
- Vol. 56 (2) , 494-501
Cell cycle inhibitors (p27Kip1 and p21CIP1) cause hypertrophy in LLC-PK1 cells
- 1 August 1999
- Published by Elsevier in Kidney International
- Vol. 56 (2) , 494-501
Cell cycle inhibitors (p27Kip1 and p21CIP1) cause hypertrophy in LLC-PK1 cells